MedTrace Logo

Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients

NCT00382044 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2008-05-23

No results posted yet for this study

Summary

The purpose of this study is to audit the effects of changing all hemodialysis patients from intravenous to subcutaneous administration of ESA's, to ensure that a cost-saving is achieved and that this does not occur at the expense of anemia control. The dose changes will occur according to usual clinical care of patients and not along a protocol.

Conditions

  • Kidney Failure, Chronic
  • Anemia

Interventions

DRUG

Eprex; Neorecormon; Aranesp

Sponsors & Collaborators

  • Sir Charles Gairdner Hospital

    lead OTHER

Principal Investigators

  • Neil C Boudville, MBBS · Sir Charles Gairdner Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-12-31
Completion
2008-04-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00382044 on ClinicalTrials.gov